<DOC>
	<DOCNO>NCT02625610</DOCNO>
	<brief_summary>The purpose study demonstrate superiority treatment avelumab versus continuation first-line chemotherapy .</brief_summary>
	<brief_title>Avelumab First-Line Gastric Cancer ( JAVELIN Gastric 100 )</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Male female subject age great equal ( &gt; = ) 18 year Disease must measurable Response Evaluation Criteria Solid Tumors version 1.1 ( RECIST 1.1 ) Subjects histologically confirm unresectable locally advanced metastatic adenocarcinoma stomach gastroesophageal junction ( GEJ ) Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) 0 1 trial entry Estimated life expectancy 12 week Adequate haematological , hepatic renal function define protocol Negative blood pregnancy test Screening woman childbearing potential Highly effective contraception male female subject risk conception exist Other protocol define inclusion criterion could apply Prior therapy antibody drug target Tcell coregulatory protein Concurrent anticancer treatment immunosuppressive agent Prior chemotherapy unresectable locally advanced metastatic adenocarcinoma stomach gastroesophageal junction ( GEJ ) Known severe hypersensitivity reaction monoclonal antibody , history anaphylaxis , uncontrolled asthma ( , 3 feature partially control asthma ) Persisting toxicity relate prior therapy except alopecia Neuropathy Grade great ( &gt; ) 3 Other protocol define exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Avelumab</keyword>
	<keyword>Cancer</keyword>
	<keyword>Unresectable</keyword>
	<keyword>Locally advanced</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Adenocarcinoma stomach</keyword>
	<keyword>Gastro-esophageal junction</keyword>
</DOC>